Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03195777
Other study ID # 2017P000808
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 20, 2017
Est. completion date March 30, 2025

Study information

Verified date January 2024
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to develop strategies that will improve outcomes for patients with deep vein thrombosis (DVT), using in vivo FDG-PET inflammation imaging to better predict the development of the post-thrombotic syndrome (PTS). New approaches are needed to improve the outcomes of patients with DVT, a disease that affects up to 600,000 patients per year in the US alone. DVT acutely places patients at risk of death from pulmonary embolism and causes 50,000 deaths annually in the US. Moreover, up to 30-50% of patients will develop PTS, an illness characterized by inflammation-driven fibrotic vein wall injury, and persistent thrombus obstruction. PTS occurs despite anticoagulant therapy, and produces chronic disability from leg pain, heaviness, edema, skin pigmentation, and ulcers; some patients may even require amputation. PTS impairs quality of life to the same extent as chronic obstructive pulmonary disease or diabetes. Therefore new diagnostic insights into PTS are urgently needed. There are several major challenges to improve outcomes in PTS: A) Limited in vivo knowledge regarding inflammation and the development of PTS; B) L Lack of predictive approaches to identify patients at high risk for PTS that will preferentially benefit from novel therapies. Recently, our laboratories have harnessed FDG-PET molecular imaging to illuminate DVT inflammation in vivo, and to provide a new strategy to diagnose recurrent DVT, a vexing clinical problem (Hara et al. Circulation 2014). We now propose to further develop FDG-PET to improve outcomes in DVT and PTS. The objective of this application is to develop FDG-PET as an inflammation imaging approach to assess DVT inflammation and predict risk of developing PTS in human subjects; Hypothesis 1A: Inflammatory activity in DVT (quantified acutely, using FDG-PET imaging within 0-7 days after DVT) will predict PTS incidence (primary) and severity (secondary) within a 24 month follow-up period. Hypothesis 1B: Inflammatory activity in DVTs (quantified sub-acutely, using FDG-PET imaging within 21-28 days after DVT), will predict PTS incidence and severity. Eighty patients with DVT will be imaged using FDG-PET/CT acutely (0-7 days of DVT diagnosis), and sub-acutely (21-28 days after diagnosis). Subjects will be evaluated repeatedly for up to 2 years to detect clinical evidence of PTS (Villalta score), ultrasound findings for structural venous injury, and soluble biomarkers of systemic inflammation. Subsequently, we will evaluate the relationship between FDG DVT activity and the development of PTS.


Description:

This study is a one-center observational study examining DVT with PET/CT. 80 individuals with recent deep venous thrombosis (DVT) will be recruited from MGH. Imaging and clinical evaluation will be performed to look for predictors of a major complication of DVT: the post-thrombotic syndrome (PTS) There are 5 visits to attend. The imaging visits will last 2-3 hours. The clinical evaluation visits will last 1-2 hours. 1. Screening - This visit will take place after initial DVT (deep venous thrombosis) diagnosis. It will involve clinical assessments and blood labs, to determine subject eligibility. If an ultrasound was not performed at the time of DVT diagnosis, an ultrasound should be performed. 2. Visit 1 (0-7 days after DVT diagnosis) - Imaging Visit 1 - At this visit, patients will receive a positron-emission tomography/ computed tomography (PET/CT) scan, and contrast-enhanced CT of the lower extremity (CTA) and will have blood labs drawn. 3. Visit 2 (21-28 days after DVT diagnosis) - Imaging Visit 2 - At this visit, patients will receive a PET/CT scan and will have blood labs drawn. 4. Visit 3 (6 months after DVT diagnosis) - Clinical Evaluation - At this visit, patients will meet to evaluate symptoms of DVT and PTS. Blood labs will be drawn. An ultrasound will be performed as well. 5. Visit 4 (24 months after DVT diagnosis OR time of PTS diagnosis) - Clinical Evaluation - At this visit, patients will meet to evaluate symptoms of DVT and PTS. Blood labs will be drawn. An ultrasound will be performed as well.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date March 30, 2025
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 30 Years and older
Eligibility Inclusion Criteria: - Age above 30 - Patient presents with a first symptomatic, proximal DVT (with or without concurrent distal DVT or pulmonary embolism). Exclusion Criteria: - Patient has May-Thurner syndrome - Patient has an expected life span of < 6 months - Patient can't receive anticoagulation therapy - Patient received thrombolytic therapy for the initial treatment of acute DVT - Patient has DVT signs of symptoms that occur more than 1 week prior to presentation, as assessed by clinical history - Renal dysfunction (Serum creatinine > 1.5 mg/ml or estimated creatinine clearance < 60 ml/min)

Study Design


Intervention

Device:
PET/CT
PET/CT imaging will be performed (with fluorodeoxyglucose, [FDG] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

References & Publications (1)

Hara T, Truelove J, Tawakol A, Wojtkiewicz GR, Hucker WJ, MacNabb MH, Brownell AL, Jokivarsi K, Kessinger CW, Jaff MR, Henke PK, Weissleder R, Jaffer FA. 18F-fluorodeoxyglucose positron emission tomography/computed tomography enables the detection of recu — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary PTS incidence Incidence of PTS (by Villalta score of =5) at any time during 24 months of observation after diagnosis of first proximal DVT 24 month follow-up period
Secondary PTS severity Maximal severity of PTS (by Villalta score) during 24 month observation 24 month follow-up period
See also
  Status Clinical Trial Phase
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT02889562 - Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Phase 2/Phase 3
Completed NCT01333618 - Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter N/A
Completed NCT00812370 - The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids Phase 1
Completed NCT02552420 - The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism Phase 2/Phase 3
Completed NCT00178789 - Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis Phase 1/Phase 2
Completed NCT03251963 - Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients Phase 2
Completed NCT03286985 - The Prevalence and Incidence of DVT in General ICU
Completed NCT04414332 - Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry
Completed NCT02211326 - Genotype-guided Warfarin Individualized Treatment N/A
Completed NCT03296280 - Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Recruiting NCT03937583 - Screening for Cancer in Patients With Unprovoked VTE Phase 4
Completed NCT00628576 - Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities Phase 3
Completed NCT04979026 - Clinical Investigation of a Novel Approach for the Prevention of Deep Venous Thrombosis After Total Knee Replacement N/A
Active, not recruiting NCT02318472 - Early Mobilization After Achilles Tendon Rupture N/A
Completed NCT01221805 - STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism Phase 4
Recruiting NCT03740633 - Functional Training for the Prevention of Deep Venous Thrombosis Phase 3
Completed NCT03707665 - Deep Venous Thrombosis Screening in the ICU by Nurses
Recruiting NCT05171049 - A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Phase 3
Completed NCT01542723 - Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy N/A